ClinicalTrials.gg
CompletedNCT02540252Amp-NuUpdated Nov 12, 2026

Nutrition and Inflammation Among Patients With Lower Limb Amputation

An observational study in Malnutrition and Inflammation, sponsored by Hvidovre University Hospital. Completed at 1 site in Denmark. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Hvidovre University Hospital · Observational

How we know

Updated Nov 12, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
49
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 42 studies in Malnutrition with a site in Denmark — 8 open to participants now, 10 under way, none of them phase 3. Malnutrition · Denmark.

Started
2015
with 3 others
Observational
7 of 42
2 open now
Registered
16th of 42
by date
Lead sponsor
4 of 42
Hvidovre University Hospital

Among the 42 studies in Malnutrition with a site in Denmark, this one is one of 4 that started in 2015, is one of 7 observational ones, and was the 16th registered.

Malnutrition

1,278 studies on the registry are indexed under Malnutrition; 231 are open to participants now.

Browse Malnutrition studies →

Open to participants now

8 of the 42 studies in Malnutrition with a site in Denmark are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 150 Malnutrition studies recruiting now, 84 (56%) set no upper age limit and 44 (29%) stop at 75 or younger; 40 take children under 18; 30 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Malnutrition with a site in Denmark, or all of them as a file.
02

Study summary

Patients with non-traumatic lower limb amputation are characterized by; high age; majority being men; multimorbidity; and high mortality. The patients comorbidities are related to diabetes and cardiovascular disorders such as arteriosclerosis.

Major surgery induces a surgical stress response that initiates a catabolic metabolism. Furthermore, the risk of systemic inflammatory response syndrome (SIRS) both before and after amputation is high (3) as the most prominent indication for amputation is gangrene, followed by non-healing or infected wounds. This leads to an impaired immune response and an increased insulin resistance that also includes a cascade of impaired appetite regulation, low dietary intake and reduced nutrient uptake form the intestine which increases inflammation, loss of muscle and risk of severe complications.

Among healthy adults with a normal weight a slow speed of eating will result in a low nutritional intake due to faster satiety experience.

Low appetite following major surgery is related to the regulation of hormone controlling the appetite. Especially older patients experience variations in appetite that affect their eating pattern such as eating speed and intake. It is therefore reasonable to assume that the speed of eating and the total nutritional intake among older patients, who are exposed to catabolic metabolism, are associated.

The hypothesis is that major surgery induces a change in patients' current eating pattern that is measurable and can be identified as a surrogate measurement of the catabolic state that is related to inflammation.

Eating Patterns are often described in clinical practice without engaging in nutritional assessment of the patient. Whether the speed of eating is an objective marker of the current nutritional status has not been established.

This study investigates patients undergoing lower limb amputation and their nutritional status, eating pattern and inflammation and whether this is linked to the current degree of disease. The purpose is to describe the development in nutritional status before and after amputation and to investigate associations between patients eating pattern and nutritional status to inflammatory and metabolic biomarkers reflecting the degree of disease.

Read the detailed description

The study is an observational cohort study that includes patients with lower limb amputation from admission to discharge.

Patients are admitted to a special amputation-unit from the outpatient clinic, the emergency department or other departments at the hospital. All patients with lower limb amputation are treated according to a rehabilitation programme that includes a multidisciplinary approach and a well-defined treatment for pain, fluid, nutrition and mobilisation.

All patients receive a standardised house diet prepared in the hospital kitchen. The diet consists of 18% protein, 40% lipids and 42% carbohydrate. The house diet is supplemented with minimum three in-between meals prepared in the dietary kitchen. The use of protein supplement is also available. Patients´ food and fluid intake are monitored daily.

Data on nutrition and eating pattern

The eating pattern is measured using a digital weight that measure gram per second. The weight is linked to a raspberry computer that recodes all output from the weight. The recording start just before the plate is placed on the weight and ends when the meal is completed. To measure appetite and hunger an arbitrary VAS scale is used to evaluate the patients´ current desire to eat, how hungry they are, how full they fell, and if they want to eat more.

The patients´ nutritional status is evaluated using Mini Nutritional Assessment (MNA). MNA is a valid tool to assess the risk of undernutrition among older people. The MNA consists of a screening tool (max 14 points, \< 11 indicates risk of undernutrition) and an evaluation tool (max 16 points). A total point \< 23,5 indicates a need for nutritional therapy.

The patients´ behaviour regarding eating and food are evaluated using Eating Identity Type Inventory (EITI). EITI consists of 8 statements that are evaluated by 5 levels of agreement.

The patients´ appetite is evaluated using Simplified nutritional Appetite Questionnaire (SNAQ). SNAQ is a tool validated to evaluate older patients´ appetite. SNAQ consists of four questions with five possible answers with a max score of 20 points. A score \<14 points indicates risk of weight loss of 5 %.

Data on Inflammation and metabolism To describe any change in inflammation or metabolic status, serum and plasma samples will be collected after inclusion, on the day of surgery and on 1, 3, 5, and 10 postoperative day. A total of 350 ml blood will be collected over a period of 12 days. The analysis is expecting to consist of inflammatory and metabolic biomarkers. All samples will be contained at minus 80 degree and minus 135 degree for immucells.

The degree of diseases will be measured using the biomarker suPAR that is associated with the degree of disease, LOS and mortality. A clinical difference is 2-3 ng/ml.

Data on protein metabolism To evaluate the protein metabolism, 10 patients undergoing above ankle amputation will have a bladder catheter inserted on the day of surgery, to collect a 24-hour urine sample. The catheter will hereafter be removed. This will be done on the 1, 5, and 10 postoperative day.

Demographic and baseline data Data on patients´ sex, age, marital status, residence, functional mobility, comorbidities, smoking and alcohol use, medications, educational and working status, and use of homecare services will be collected. The patients´ muscle strength is measured using handgrip strength on the dominant hand prior to surgery and on the 5, 10 postoperative day and at discharged.

Complications Complications during hospitalisation will be registered and categorised as; cardio or respiratory, metabolic, infection and lack of healing, re-amputation or revision within 30 days, and 30 day mortality.

The analysis of data will include an investigation of: whether suPAR is dependent on nutritional intake whether; patients' eating pattern can be used as an objective description of the current nutritional status; inflammation is dependent on nutritional intake; complications are dependent on nutritional intake. We will also investigate protein metabolism after lower limb amputation.

Power calculation The aim of the study is to describe the associations between the patients eating pattern and nutritional status and the degree of disease among older patients undergoing lower limb amputation.

We calculated that; with a power of 80%; a statically significant level of 5%; a minimum difference in suPAR at 2,5ng/ml between patients who receive sufficient nourishment or not (assuming that 50% of all patients achieve sufficient nourishment during hospitalisation) and a SD at 2.8 ng/ml (suPAR) the number of included patients should be 42. An estimated dropout set at 20 % (8 patients) results in a inclusion of 50 patients.

The primary outcome is a change in suPAR, a biomarker related to the degree of disease, hospitalization and death. The outcome will be measured before and 10 days after surgery.

The secondary outcomes are; nutritional intake measured as daily protein (g/kg) and energy (kilojoule/kg) intake, eating rate measured as g/min, total length of the meal, activity (activity on the plate compared with intake), biomarkers for inflammation and metabolism; protein balance measured as urine urea nitrogen in a 24-hour urine sample; revisions and re-amputation; LOS and 30 day mortality.

03

Conditions studied

  • Malnutrition
  • Inflammation

Keywords

  • Lower Limb Amputation
  • Nutrition
  • Eating
  • Inflammation
  • Nursing
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients are included from a cohort of patients who are admitted to the Department of Ortopedic Surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having a medical indication for amputation
  • Admitted with a non healing wound on lower limb
  • Revision following previous amputation
  • Able to speak and understand Danish - able to give an

Exclusion criteria

Exclusion Criteria:

  • Traumatic or pathologic indication for amputation
  • Any or current use of narcotics
  • Major surgery within the last four weeks
  • If not amputated two weeks after admission
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
49 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • OtherNutritional status among patients with lower limb amputation

    Patients nutritional status, inflammatory and metabolic pathway are observed during their hospitalization.

    Also known as: Inflammation and metabolic pathway

06

What researchers measure

Primary outcomes

  1. suPAR

    Soluble urokinase plasminogen activator receptor: Biomarker of low-grade inflammation. suPAR are measured prior to surgery and on the 1, 3, 5 and 10 postoperative day and will be compared to patients daily intake of energy (kilojoule) and protein (gram)

    Time frame: From admission to ten days after surgery

Secondary outcomes

  1. Inflammatory biomarkers such as IL6, IL10,IL18, TNF-a, MCP-1, sCD14, C reactive protein, expression of inflammatory genes from immucell

    Biomarkers of low-grade inflammation. Inflammatory biomarkers will be measured in duplicates in serum or plasma using commercially available Luminex or ELISA kits according to the manufactures instructions. Cytokines with low systemic levels such as IL-6 and TNF-α will be measured with high sensitive kits to ensure detection. Samples are stored in a biobank established for the project at -80°C. Inflammatory biomarkers are measured simultaneously when all patients have been included.

    Time frame: From admission to ten days after surgery

  2. Metabolic biomarkers such as Insulin, Glucose, Adiponectin, Leptin, Ghrelin

    Biomarkers of metabolic pathway Glucose is measured in blood at each visit using the HemoCue® system. All other metabolic biomarkers will be measured in duplicates in serum or plasma using commercially available Immulite, Luminex or ELISA kits according to the manufactures instructions. Samples are stored in a biobank established for the project at -80°C. Metabolic biomarkers except for glucose are measured simultaneously when all patients have been included.

    Time frame: From admission to ten days after surgery

  3. Postoperative LOS from surgery to medical stability (planned disharge)

    The LOS are measured from the admission day to the unit and to the day the patients medical treatment are completed

    Time frame: From surgery to discharge

  4. Revisions or re-amputation

    A Revision after amputation is defined as a surgical invasive procedure that aims to improve healing of the stump. A re-amputation is also defined as a surgical invasive procedure that includes amputation on a higher level

    Time frame: From surgery to discharge

  5. Severity of Infections

    Infections are categorised in; sepsis, deep wound infections that is treated with antibiotics and superficially wound infections.

    Time frame: From surgery to discharge

  6. Eating patterns (eating time, intake )

    Eating pattern are measured as speed of eating (gram per minutes), the time for the total meal (minutes) and total intake (gram).

    Time frame: From surgery to ten days after surgery

  7. Secondary analysis 1: Descriptions of the nutritional status during hospitalisation 2: Nutritional status at disharge, dependency of morbitity

    1. Nutritional intake is measured in protein (gram) and energy (Kilojoule). The nutritional intake is monitored daily from inclusion to 10 postoperative day. 2. The nutritional status at discharge measured as difference in bodyweight from admission. Morbidity are defined as any chronical disease registered using ICG 10 code

    Time frame: 1: From admission to 10 postoperative day 2: Nutritional status at discharge

  8. Protein metabolism

    Analysis of 24 hour urine sample among 10 patients undergoing major lower limb amputation. The protein metabolism will be measured as U-Carbamide (mmol) that are converted to the level of nitrogen and then compared to the daily protein intake to estimate the balance of protein.

    Time frame: Will be mesured on the 1, 5, and 10 postoperative day

  9. Monocytic Myeloid-derived Suppressor Cells (mMDSCs)

    mMDSC are measured by FACS analyses in cryopreserved peripheral blood mononuclear cells

    Time frame: Measured at inclusion, and at day 10 after amputation, and at inclusion for Controls

  10. Sirtuin 1 (SIRT1)

    SIRT1 along with other factors regulating hypoxia, inflammation, and catabolism such as hypoxia-inducible factor (HIF)-1a, nuclear factor k B (NF-kB), and forkhead box protein (Fox) O1 are measured in muscle biopsies from patients and controls. Muscle biopsies are submerged in All Protect (Quiagen) immediately after acquisition, and stored at least overnight, before transferral to a new cryo-vial. Muscle biopsies are stored at -80C until analyses.

    Time frame: Measured in muscle biopsies taken in the beginning of the amputation for patients, and at inclusion for Controls

07

Study locations

1 site
  • University Hospital of Copenhagen, Hvidovre
    Hvidovre, Copenhagen 2650, Denmark
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Nov 2016, 14 months.

Of 175 non-industry observational studies under Malnutrition, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's 14 months is below that.

Counting every sponsor, half of 187 studies reached it within 21 months; a quarter within 11 and three quarters within 41.

Completion moved once since we started tracking on Sep 25, 2026: Apr 2017 → Nov 2017, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2015
First posted
Sep 3, 2015
StartActual
Aug 19, 2015
Primary completionActual
Nov 1, 2016
CompletionActual
Nov 13, 2017was Apr 2017
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 12, 2026
Primary completion
Nov 13, 2016→Nov 1, 2016
Nov 12, 2026
Study completion
Apr 2017→Nov 13, 2017 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Status unknown→Completed
    Primary completion Nov 13, 2016→Nov 1, 2016
    Study completion Apr 2017→Nov 13, 2017 (now actual)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02540252
Responsible party
Ove Andersen (Research Director, Hvidovre University Hospital) — Principal investigator
First posted
Sep 3, 2015
Start date
Aug 19, 2015
Primary completion
Nov 1, 2016
Completion
Nov 13, 2017
Last update
Nov 12, 2026

Study contacts

Ove Andersen, PHD,MD
principal investigator · Clinical Research Centre, University Hospital of Copenhagen, Hvidovre

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion